论文部分内容阅读
美国Cel-Sci公司开发了一项比较简便的技术,为许多本身没有足够效力的肽疫苗提供了希望.最近公司在小鼠疱疹病毒疫苗实验中证实了此方法.Cel-Sci公司的技术称为配体表位抗原提呈系统(LEAPS),它是将肽抗原和T细胞结合肽连接起来.公司报道在16只免疫LEAPS疫苗的小鼠中15只能抵御随后的疱疹病毒攻击.Cel-Sci公司Kersten称,虽然公司正在人类免疫缺陷症病毒(HIV)疫苗和结核菌苗中试验LEAPS,但是疱疾病毒仍将是第一候选物,并将进入临床试验.先前公司
Cel-Sci, Inc. of the United States has developed a relatively simple technique that has offered promise for many peptide vaccines that do not have sufficient potency in their own right, and the company recently demonstrated this in a mouse herpes virus vaccine experiment. The technology of Cel-Sci called Ligand Epitopes Antigen Presentation System (LEAPS), which links peptide antigens to T cell binding peptides, has reported that 15 of 15 mice vaccinated with LEAPS vaccine are resistant to subsequent herpes simplex virus attacks.Cel-Sci Company Kersten said that although the company is testing LEAPS in human immunodeficiency virus (HIV) vaccines and TB vaccines, the blister virus will remain the number one candidate and will enter clinical trials. Previous companies